These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36530994)

  • 41. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
    Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
    Kuo MT; Savaraj N; Feun LG
    Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic Polymorphism of Epidermal Growth Factor Gene as a Predictor of Hepatocellular Carcinoma in Hepatitis C Cirrhotic Patients.
    Baghdadi I; Abu Ella K; El Shaaraway A; Elshayeb E; El-Rebey HS; El Hoseeny M; Naguib M; Nada A
    Asian Pac J Cancer Prev; 2020 Jul; 21(7):2047-2053. PubMed ID: 32711431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Single Nucleotide Polymorphisms in
    Bei C; Liu S; Yu X; Qiu M; Tang B; Liao W; He S; Yu H
    Biomed Res Int; 2018; 2018():1540201. PubMed ID: 30662901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
    Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
    Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.
    Miraki-Moud F; Ghazaly E; Ariza-McNaughton L; Hodby KA; Clear A; Anjos-Afonso F; Liapis K; Grantham M; Sohrabi F; Cavenagh J; Bomalaski JS; Gribben JG; Szlosarek PW; Bonnet D; Taussig DC
    Blood; 2015 Jun; 125(26):4060-8. PubMed ID: 25896651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
    Izzo F; Montella M; Orlando AP; Nasti G; Beneduce G; Castello G; Cremona F; Ensor CM; Holtzberg FW; Bomalaski JS; Clark MA; Curley SA; Orlando R; Scordino F; Korba BE
    J Gastroenterol Hepatol; 2007 Jan; 22(1):86-91. PubMed ID: 17201887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SNP rs2057482 in HIF1A gene predicts clinical outcome of aggressive hepatocellular carcinoma patients after surgery.
    Guo X; Li D; Chen Y; An J; Wang K; Xu Z; Chen Z; Xing J
    Sci Rep; 2015 Jun; 5():11846. PubMed ID: 26115041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of IL-2 polymorphisms and IL-2 serum levels with susceptibility to HBV-related hepatocellular carcinoma in a Chinese Zhuang population.
    Peng Q; Li H; Lao X; Deng Y; Chen Z; Qin X; Li S
    Infect Genet Evol; 2014 Oct; 27():375-81. PubMed ID: 25173083
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Lin WR; Hsu CW; Chen YC; Chang ML; Liang KH; Huang YH; Yeh CT
    Mol Clin Oncol; 2014 Jul; 2(4):630-640. PubMed ID: 24940508
    [TBL] [Abstract][Full Text] [Related]  

  • 51. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.
    Liang KH; Lin CC; Yeh CT
    Pharmacogenomics; 2011 Jul; 12(7):1061-73. PubMed ID: 21635146
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
    Chan PY; Phillips MM; Ellis S; Johnston A; Feng X; Arora A; Hay G; Cohen VML; Sagoo MS; Bomalaski JS; Sheaff MT; Szlosarek PW
    Pigment Cell Melanoma Res; 2022 Jul; 35(4):461-470. PubMed ID: 35466524
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.
    Mörén L; Perryman R; Crook T; Langer JK; Oneill K; Syed N; Antti H
    BMC Cancer; 2018 Feb; 18(1):167. PubMed ID: 29422017
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of Notch receptors in postsurgical patients with hepatitis B virus-related hepatocellular carcinoma.
    Yu T; Han C; Zhu G; Liao X; Qin W; Yang C; Liu Z; Su H; Liu X; Yu L; Liu Z; Lu S; Chen Z; Liang Y; Huang J; Qin X; Gui Y; Li J; Peng T
    Cancer Med; 2017 Jul; 6(7):1587-1600. PubMed ID: 28568708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The contribution of caveolin-1 genotype and phenotype to hepatocellular carcinoma.
    Hsu CM; Yang MD; Tsai CW; Ho CY; Chang WS; Chang SC; Jeng LB; Tsai Y; Tsai FJ; Bau DT
    Anticancer Res; 2013 Feb; 33(2):671-7. PubMed ID: 23393366
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy.
    Hu W; Huang S; Dong L; Yu C; Li C; Zhang J
    Anticancer Drugs; 2019 Mar; 30(3):233-240. PubMed ID: 30779721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.
    Terashima T; Honda M; Toyama T; Shimakami T; Shimizu R; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1813-1820. PubMed ID: 32180251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A genetic variant (rs17251221) in the calcium-sensing receptor relates to hepatocellular carcinoma susceptibility and clinical outcome treated by transcatheter hepatic arterial chemoembolization (TACE) therapy.
    Tang Q; Zhao Y; Wang Y; Wei M
    Med Oncol; 2014 Nov; 31(11):267. PubMed ID: 25270285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LncRNA WWOX-AS1 sponges miR-20b-5p in hepatocellular carcinoma and represses its progression by upregulating WWOX.
    Xu D; Liu X; Wu J; Wang Y; Zhou K; Chen W; Chen J; Chen C; Chen L
    Cancer Biol Ther; 2020 Oct; 21(10):927-936. PubMed ID: 32931356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy.
    Long Y; Tsai WB; Wang D; Hawke DH; Savaraj N; Feun LG; Hung MC; Chen HH; Kuo MT
    Cancer Lett; 2017 Mar; 388():54-63. PubMed ID: 27913198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.